Multifunctional inhibitors of biological MEK / PI3K and MTOR / MEK / PI3K pathways and therapeutic procedures using the same
Patent Information
- Application Number
- DE602017086792
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-02-03
- Filing Date
- 2017-07-06
- Publication Date
- 2024-12-11
- Estimated Expiration
- 2037-07-06
AI Technical Summary
Current treatments for KRAS-activated cancers, particularly pancreatic and colorectal cancers, are limited due to the challenge of directly targeting mutant KRAS, with existing inhibitors showing restricted efficacy and resistance mechanisms, necessitating the development of multifunctional agents that can effectively inhibit key signaling pathways like mTOR, MEK, and PI3K.
Development of novel multifunctional compounds that co-target mTOR, MEK, and PI3K pathways by chemically modifying individual inhibitors to maintain high binding affinity, allowing for simultaneous inhibition of these critical regulatory nodes and intercepting cross-talk between their pathways.
These compounds demonstrate potent inhibition of tumor growth and metastasis by simultaneously targeting mTOR, MEK, and PI3K, offering improved therapeutic options for KRAS mutant tumors and potentially reducing patient mortality by enhancing cancer therapy regimens.